Please assess the completion status of the following clinical trial:

Trial Title: Assessing Neurocognitive Effects of Gluten Exposure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female~2. 18-50 years of age~3. Celiac Disease Group: Positive small intestinal biopsies meeting Marsh II or III histologic criteria for celiac disease at least six months since the time of study entrance as well as positive IgA anti-tissue transglutaminase antibody or positive IgA/IgG anti-Deamidated Gliadin Peptide (DGP) with normal serum IgA~4. Non-Celiac Gluten Sensitive Group: Negative small intestinal biopsies and negative IgA anti-tissue transglutaminase (tTG) or negative IgA/IgG anti-Deamidated Gliadin Peptide (DGP) with normal serum IgA, but with symptomatic response to gluten withdrawal~5. Subject should have well controlled celiac disease and have been on a gluten-free diet for at least six months prior to study enrollment~6. Subject must provide informed consent, as approved by the Institutional Review Board, and agree to complete required study visits, blood work neuropsychological testing and a urine pregnancy test (if applicable).~7. Subject agrees to use appropriate birth control for the duration of the study.~Exclusion Criteria:~1. Subject has other food intolerances or food allergies (other than gluten) that would interfere with the conduct of the study (e.g. corn starch, soy).~2. Subject has a history of severe, acute symptomatic reactions to sporadic gluten ingestion~3. Subject has any chronic active gastrointestinal disease other than celiac disease (e.g. Crohn's disease, irritable bowel syndrome, autoimmune enteropathy, eosinophilic enteritis).~4. Subject should not have daily symptoms concerning for brain fog such as mental confusion or difficulty concentrating, at baseline.~5. Subject has symptomatic neurological or psychiatric disease(s) that would interfere with the conduct of the study.~6. Subject should not have been on corticosteroids or other immunosuppressive agents in the past 3 months.~7. Significant other co-morbidity as determined by the Principal Investigator~8. Subject is deemed inappropriate by the Principal Investigator.~9. Subject is pregnant or breast-feeding at time of participation.~10. Subject weighs less than 110 pounds.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Crossover Group 1 (Type: EXPERIMENTAL): Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.~Group 1 will consume placebo before neurocognitive testing at Visit 3.
- Crossover Group 2 (Type: EXPERIMENTAL): Group 2 will consume placebo before neurocognitive testing at Visit 2.~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).